Latest Breaking News On - Therapy designation - Page 6 : comparemela.com

Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics Receives Breakthrough Therapy

First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned.

Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline

By Chris Wack Soleno Therapeutics said that the Food and Drug Administration has granted Breakthrough Therapy Designation for diazoxide choline extended-release tablets for the treatment.

Ono Pharmaceutical : Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

Osaka, Japan and Waltham, Massachusetts, April 30, 2024 - ONO Pharmaceutical, Co., Ltd., and Deciphera Pharmaceuticals, Inc. today announced that on April 29, 2024 , ONO and Deciphera entered.

Cybin to Participate at the 27th Annual Milken Institute Global Conference

- Doug Drysdale, CEO, to appear on panel entitled “Collaborating for Improved Mental Health,” on May 8, 2024 - .